Program
Autologous Clonal Neoantigen T Cells ATL001
Also written as “ATL001” and “ATL-001 (Ciclopirox oral solution)”.
Its studies are mostly in Porphyria, Erythropoietic · Carcinoma, Non-Small-Cell Lung · Melanoma, led by 2 companies.
Drug pageAutologous Clonal Neoantigen T Cells ATL001: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Achilles Therapeutics UKits history only | 20 open or running | phase 2since Feb 4, 2019 | Feb 4, 2019 | none ahead |
| Atlas Molecular Pharmaits history only | 11 open or running | phase 2since Jun 3, 2025 | Jun 3, 2025 | May 1, 2028phase 2 · NCT07024316 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 4, 2019First study: phase 2 study in MelanomaNew to Achilles Therapeutics UKAchilles Therapeutics UK · NCT03997474 · 13 enrolled · Spain, United Kingdom
- Jul 17, 2019Phase 2 study in Advanced Non Small Cell Lung CancerAchilles Therapeutics UK · NCT04032847 · 27 enrolled · United States, France, Germany and more
- Jun 3, 2025Atlas Molecular Pharma’s first study: phase 2 study in Porphyria, ErythropoieticNew to Atlas Molecular PharmaAtlas Molecular Pharma · NCT07024316 · 6 planned · United States
Ahead
- May 1, 2028Primary completion: phase 2 study in Porphyria, ErythropoieticAtlas Molecular Pharma · NCT07024316
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07024316Porphyria, Erythropoietic · United States | 2 | Recruiting | Atlas Molecular Pharma | May 1, 2028 | 6 |
| NCT04032847Advanced Non Small Cell Lung Cancer · United States, France, Germany and more | 2 | Terminated | Achilles Therapeutics UK | Sep 26, 2024 | 27 |
| NCT03997474Melanoma · Spain, United Kingdom | 2 | Terminated | Achilles Therapeutics UK | Sep 3, 2024 | 13 |
How it is read
Names in the registry
- “ATL001”, 2 entries
- “ATL-001 (Ciclopirox oral solution)”, 1 entry
Conditions, from the studies’ own filings
- Porphyria, Erythropoietic, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.